The Dexcom G7 is an FDA-cleared continuous glucose monitor that measures glucose every 5 minutes without fingersticks or scanning. Approved for ages 2 and older across all diabetes types, it combines the sensor and transmitter into a single all-in-one wearable worn on the upper arm or abdomen.
The G7 delivers an 8.2% MARD accuracy rating and a 30-minute warm-up, a dramatic cut from the 2-hour warm-up on the G6. The device integrates with four major AID pump systems and sends customizable alerts to smartphones and Apple Watch. Coverage spans most private insurance plans, Medicare Part B, and Medicaid.
This review covers how the Dexcom G7 works, what real users actually report after daily wear, how it stacks up against the Freestyle Libre 3 on accuracy and price, what it costs with and without insurance, and whether the G7’s features justify the investment for people managing diabetes with insulin.
What Is the Dexcom G7 Glucose Sensor?
The Dexcom G7 is an FDA-cleared continuous glucose monitoring (CGM) system that combines the sensor and transmitter into a single all-in-one wearable device. FDA approved it for adults in 2022 and expanded that clearance to children ages 2 and older in 2023. Here’s the key part: it requires no fingerstick calibration and no manual scanning at any point during its wear period.
The Dexcom G7 works for type 1, type 2, and gestational diabetes. Ages 7 and older wear it on the back of the upper arm. Children ages 2 to 6 wear it on the upper buttocks instead.
Who Can Use the Dexcom G7:
- People with type 1 diabetes
- People with type 2 diabetes
- People with gestational diabetes
- Children ages 2 and older
- Adults of all ages
How Does the Dexcom G7 Work?
The G7 sensor tip sits in the interstitial fluid just below the skin, where it uses a glucose oxidase enzyme to continuously measure glucose concentration. The transmitter converts that chemical reaction into an electronic signal. An internal algorithm then calculates a glucose value in mg/dL or mmol/L, depending on location.
The system sends glucose readings every 5 minutes via Bluetooth to a compatible smartphone or Apple Watch. No phone? The dedicated G7 receiver is an option. It weighs 4 oz (113 g) and holds a charge for up to 7 days.
The G7 app shows the current glucose value, a trend arrow, and a full glucose history graph. Users can toggle between 1, 3, 6, 12, and 24-hour views directly in the app.
How Long Does the Dexcom G7 Sensor Last?
The Dexcom G7 sensor lasts up to 10 days, followed by an additional 12-hour grace period that extends total wear to 10.5 days before a replacement is needed. That grace window is more useful than it sounds. It gives users room to apply a new sensor without scrambling or losing coverage.
Dexcom also makes the G7 15-Day variant. Total wear time there is 15.5 days, including the same 12-hour grace period. That version is approved for ages 18 and older. Its MARD is 8.0%, a slight improvement over the standard G7’s 8.2%.
Here’s what most people do: they overlap sensors. A new one goes on while the old one is still reading. The 30-minute warm-up finishes before the old session ends. The result? Zero gap in monitoring. Not a single missed reading during the switch.
What Are the Key Features of the Dexcom G7?
The Dexcom G7 delivers a measurable set of improvements over previous CGM generations, including a 60% smaller form factor than the G6, factory calibration, and compatibility with four major automated insulin delivery systems. These aren’t just marketing claims. They’re the reasons CGM users actually switched.
No fingerstick calibration required. Sensors ship factory calibrated. Fingersticks are only recommended when the displayed reading doesn’t match how the user feels. That’s it.
Compatible Insulin Pump Systems:
- Omnipod 5 by Insulet Corporation
- iLet Bionic Pancreas System
- Tandem Mobi System
- Tandem t:slim X2 with Control-IQ Technology
Is the Dexcom G7 Accurate?
Yes. The Dexcom G7 achieves a mean absolute relative difference (MARD) of 8.2%, placing it among the most accurate CGMs available without requiring calibration from the user. The lower the MARD number, the better the accuracy. So 8.2% is a strong result.
The G7 holds its accuracy during rapid glucose changes and at extreme glucose levels. That matters most for insulin-dependent users who need reliable readings right when glucose is moving fast or sitting dangerously low.
The FDA awarded the G7 the iCGM designation. That label means the G7 meets stricter accuracy thresholds than standard CGMs. Bottom line: iCGM status is the reason the G7 can connect directly to automated insulin pumps without extra validation steps.
Does the Dexcom G7 Have a Faster Warm-Up Time?
Yes. The Dexcom G7 warms up in just 30 minutes, compared to the 2-hour warm-up required by the G6 and the 60-minute or longer warm-up required by most competing CGM systems. That improvement alone changed how people manage sensor transitions.
Think of it this way: with a 30-minute warm-up, users can apply the new sensor while the old one is still running. By the time the old session ends, the new one is already reading. No waiting. No gap. No scrambling.
Warm-Up Time Comparison:
| CGM Device | Warm-Up Time |
| Dexcom G7 | 30 minutes |
| Dexcom G6 | 2 hours |
| Freestyle Libre 3 | 60 minutes |
| Medtronic Guardian 4 | 2 hours |
What Do Dexcom G7 Reviews Say?
Dexcom G7 reviews consistently call out the smaller size, faster warm-up, and improved usability as the biggest upgrades over the G6, the model it replaced when G7 launched in the U.S. in early 2023. Reception from the diabetes community was strong almost immediately.
Justin Eastzer is a type 1 diabetes content creator diagnosed in 2021. He’s been using the G7 since February 2023. His top two features? The 30-minute warm-up and the 12-hour grace period. Both, he said, make sensor transitions seamless in a way the G6 never managed.
What Are Users Saying About the Dexcom G7?
Users praise the Dexcom G7 for its 60% size reduction compared to the G6, which means the sensor snags on clothing and surfaces far less during daily movement and exercise. Smaller also means more discreet. That matters for users who wear it visibly on the arm.
Real-time alerts to Apple Watch and Android smartwatches rank high in user feedback. The good news? No reaching for the phone. A quick wrist glance shows the current reading, trend arrow, and any active alerts. For active users, that’s a meaningful quality-of-life difference.
Top User-Praised Features:
- 60% smaller sensor than the Dexcom G6
- 30-minute warm-up enabling seamless sensor overlap
- 12-hour grace period for flexible sensor transitions
- Direct-to-Apple Watch and smartwatch glucose alerts
- Real-time high and low glucose notifications
What Are the Most Common Complaints About the Dexcom G7?
The most frequent complaint about the Dexcom G7 involves skin irritation and adhesive reactions at the sensor insertion site, particularly for users with sensitive skin or known adhesive allergies. Redness, itching, and patch-edge peeling are the most commonly reported issues.
Some users also note accuracy drift in the final 24 to 48 hours of the 10-day wear period. Dexcom’s guidance is consistent here: perform a fingerstick check whenever the reading doesn’t match how the user feels. That applies at any point in the wear cycle, not just at the end.
How Does the Dexcom G7 Compare to the Freestyle Libre 3?
The Dexcom G7 sends proactive real-time alerts for highs, lows, and predicted urgent lows, while the Freestyle Libre 3 also streams continuous data with alerts but offers fewer integration options for automated insulin delivery pump systems. Both hold FDA’s iCGM designation.
Here’s the biggest differentiator: insulin pump compatibility. The G7 integrates with four AID systems. The Libre 3 works with fewer options. For anyone running a closed-loop setup, that difference is often the deciding factor.
On price, the G7 costs more per month than the Libre 3 without insurance. But here is the thing: Dexcom is the most widely covered CGM brand across private insurance, Medicare, and Medicaid. For many users, coverage closes that gap significantly or eliminates it entirely.
Dexcom G7 vs Freestyle Libre 3 Comparison:
| Feature | Dexcom G7 | Freestyle Libre 3 |
| MARD Accuracy | 8.2% | ~7.8% (Libre 3 Plus) |
| Warm-Up Time | 30 minutes | 60 minutes |
| Wear Duration | 10 days + 12 hr grace | 14 days |
| Real-Time Alerts | Yes | Yes |
| Insulin Pump AID | 4 systems | Limited |
| Medicare Coverage | Yes | Yes |
Which CGM Is More Accurate?
The Dexcom G7 achieves a MARD of 8.2%, while the Freestyle Libre 3 Plus reports a MARD of approximately 7.8%, giving the Libre 3 Plus a slight numerical advantage in published head-to-head accuracy data. Both devices carry the FDA’s iCGM designation.
In practice, accuracy comparisons depend on the study population and glucose ranges tested. The G7’s performance during rapid glucose changes and in the hypoglycemic range is well-documented in peer-reviewed studies published in journals including Diabetes Care.
Are There Side Effects From Using the Dexcom G7 Sensor?
The most common side effects of the Dexcom G7 are mild skin reactions at the insertion site, including redness, bruising, itching, or irritation from the adhesive patch that holds the sensor against the skin. In most cases, these reactions are temporary and clear up after the sensor is removed.
Users with adhesive sensitivities manage the problem by applying a barrier film like Skin Tac under the sensor before placing it. Others add supplemental tape around the sensor edges. Both approaches reduce direct skin contact with the adhesive and minimize edge peeling in high-sweat conditions.
Reported Side Effects:
- Localized redness at insertion site
- Skin bruising around sensor tip
- Itching or irritation from adhesive patch
- Patch-edge peeling in high-sweat environments
Who Should Avoid the Dexcom G7?
The Dexcom G7 must be removed before MRI scans, CT scans, X-rays, or diathermy procedures, as the sensor and transmitter are vulnerable to damage from these imaging environments and may interfere with results. Medical teams should know about any active CGM before scheduling imaging.
Unlike older CGM models, the G7 is not affected by standard doses of acetaminophen (paracetamol). That’s an important improvement. Earlier generations required users to factor in medication interference whenever interpreting readings after taking common pain relievers.
Is the Dexcom G7 Waterproof?
Yes. The Dexcom G7 is rated waterproof at depths up to 2.4 meters (8 feet) for up to 24 hours. That covers showers, baths, swimming pools, and water sports throughout its entire 10-day wear period. No waterproof cover or protective sleeve is needed.
The sensor stays on through sweat, swimming, and daily hygiene without any special prep. The adhesive patch was designed to handle repeated water exposure and still maintain a secure bond on the skin throughout the full wear cycle.
Is the Dexcom G7 FDA Approved?
Yes. The Dexcom G7 received FDA clearance for adults in 2022 and expanded clearance to children ages 2 and older in 2023, covering type 1, type 2, and gestational diabetes across all eligible age groups. The device also carries the iCGM designation, the FDA’s highest accuracy standard for CGMs used with automated systems.
The iCGM label isn’t cosmetic. It requires meeting stricter accuracy thresholds than general CGM devices. Without iCGM status, a CGM cannot legally communicate directly with insulin pumps or other automated diabetes management systems. The G7 meets that standard.
How Much Does the Dexcom G7 Cost?
The Dexcom G7 retails at approximately $349 (USD) for a 3-sensor pack covering a 30-day supply without insurance, with individual sensors priced at roughly $116 each at full retail. For users without coverage, that’s the ceiling. Insurance and Medicare bring the cost down substantially.
Dexcom’s subscribe-and-save program cuts up to 15% off recurring sensor orders placed through the Dexcom store. The G7 receiver is optional. Users who prefer the smartphone app don’t need to buy it.
Is the Dexcom G7 Covered by Insurance?
Yes. The Dexcom G7 is covered by most major private insurance plans, Medicare Part B, and Medicaid for eligible patients, which is why Dexcom consistently ranks as the most widely covered CGM brand in the U.S.
Medicare Part B covers CGMs for qualifying patients, typically those using insulin. The G7 meets Medicare’s coverage criteria. Users unsure of eligibility can verify directly with Dexcom or call their insurance provider before placing an order.
Is the Dexcom G7 Worth the Price?
For insulin-dependent users, the Dexcom G7 delivers documented clinical value, including lower A1C levels and higher time in target glucose range, outcomes confirmed in multiple peer-reviewed studies comparing CGM use against traditional fingerstick monitoring.
The G7 also replaces fingerstick consumables. Test strips, lancets, and lancing devices add up for users checking glucose 4 to 8 times daily. The CGM cost gap versus traditional monitoring narrows once those ongoing consumable costs are factored out.
Where Can You Buy the Dexcom G7?
The Dexcom G7 is available with a valid prescription through Dexcom.com, major retail pharmacies including CVS and Walgreens, and diabetes supply companies such as US MED, which handles insurance billing and ships directly to the patient’s home.
Dexcom also runs a free G7 trial program. Eligible new users submit a prescription online and receive a trial sensor kit. It’s a no-pressure way to test the system before committing to a full order or routing it through insurance billing.
Where to Buy the Dexcom G7:
- Dexcom.com (official store and free trial)
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- US MED (insurance billing and home delivery)
Is the Dexcom G7 Worth It?
The Dexcom G7 is one of the most accurate CGMs on the market, with an 8.2% MARD, a 30-minute warm-up, waterproof construction, and compatibility with four major AID pump systems. For insulin-dependent users, it is the strongest real-time glucose monitoring option available.
The G7 is the right pick for people with type 1 diabetes and insulin-dependent type 2 diabetes, especially those running a closed-loop system or relying on overnight hypoglycemia alerts. With insurance or Medicare coverage, the monthly cost becomes comparable to what traditional fingerstick testing runs over the same period.